TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material
1996

TP53 Mutation Analysis in Breast Cancer Samples

Sample size: 186 publication Evidence: moderate

Author Information

Author(s): S Gretarsdottir, L Tryggvadottir, JG Jonasson, H Sigurdsson, K Olafsdottir, BA Agnarsson, H Ogmundsdottir, JE Eyfjord

Primary Institution: Icelandic Cancer Society, University Hospital, Reykjavik, Iceland

Hypothesis

Can TP53 mutations be analyzed in archival paraffin-embedded breast carcinoma samples using the CDGE method?

Conclusion

The study found that TP53 mutations can be analyzed in archival breast cancer samples, and those with mutations had a significantly shorter post-recurrence survival.

Supporting Evidence

  • TP53 mutations were detected in 30 samples (16.1%) and confirmed by sequencing in 17 cases.
  • Immunohistochemistry showed TP53 nuclear accumulation in 58 tumours (31%).
  • A strong association between TP53 mutations and immunostaining was observed (P<0.001).
  • Patients with abnormal TP53 had a significantly shorter post-recurrence survival (P=0.005).

Takeaway

Researchers looked at old breast cancer samples to see if they had changes in a gene called TP53, which helps control cell growth. They found that some samples had these changes, and patients with them didn't do as well after their cancer came back.

Methodology

DNA was extracted from 193 archival primary breast carcinoma samples, and TP53 mutations were analyzed using constant denaturant gel electrophoresis (CDGE).

Limitations

The study was limited by the quality of DNA from archival samples, which may affect the clarity of results.

Participant Demographics

Median age at diagnosis was 62 years, with a range from 31 to 91 years.

Statistical Information

P-Value

p=0.005

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication